|
注册号: Registration number: |
ChiCTR2500111947 |
|
最近更新日期: Date of Last Refreshed on: |
2025-11-07 15:58:39 |
|
注册时间: Date of Registration: |
2025-11-07 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
1型糖尿病遗传风险评分对糖尿病患者进展为胰岛素 缺乏的预测价值:一项多中心巢式病例对照研究 |
|
Public title: |
Genetic risk score of type 1 diabetes mellitus for progression to insulin in diabetic patients Lack of predictive value: a multicenter nested case-control study |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
1型糖尿病遗传风险评分对糖尿病患者进展为胰岛素 缺乏的预测价值:一项多中心巢式病例对照研究 |
|
Scientific title: |
Genetic risk score of type 1 diabetes mellitus for progression to insulin in diabetic patients Lack of predictive value: a multicenter nested case-control study |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
胡婧宜 |
研究负责人: |
肖扬 |
|
Applicant: |
Jingyi Hu |
Study leader: |
Yang Xiao |
|
申请注册联系人电话: Applicant telephone: |
+86 731 85295999 |
研究负责人电话:
Study leader's |
+86 13574848588 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
hujingyi0066@csu.edu.cn |
研究负责人电子邮件: Study leader's E-mail: |
xiaoyang29@hotmail.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
湖南省长沙市芙蓉区人民中路139号 |
研究负责人通讯地址: |
湖南省长沙市芙蓉区人民中路139号 |
|
Applicant address: |
No. 139 Renmin Middle Road, Furong District, Changsha City, Hunan Province |
Study leader's address: |
No. 139 Renmin Middle Road, Furong District, Changsha City, Hunan Province |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
中南大学湘雅二医院 |
||
|
Applicant's institution: |
The Second Xiangya Hospital of Central South University |
||
|
研究负责人所在单位: |
中南大学湘雅二医院 |
||
|
Affiliation of the Leader: |
The Second Xiangya Hospital of Central South University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
(2025)国伦审[科]第(K028)号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
中南大学湘雅二医院国家临床医学研究中心伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of National Clinical Research Center,The Second Xiangya Hospital of Central South University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-09-29 00:00:00 | ||
|
伦理委员会联系人: |
颜湘 |
||
|
Contact Name of the ethic committee: |
Xiang Yan |
||
|
伦理委员会联系地址: |
湖南省长沙市芙蓉区人民中路139号 |
||
|
Contact Address of the ethic committee: |
No. 139 Renmin Middle Road, Furong District, Changsha City, Hunan Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 731 85295391 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
yanxiang@csu.edu.cn |
|
研究实施负责(组长)单位: |
中南大学湘雅二医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The Second Xiangya Hospital of Central South University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
湖南省长沙市芙蓉区人民中路139号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 139 Renmin Middle Road, Furong District, Changsha City, Hunan Province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
自选课题(自筹) |
||||||||||||||||||||||
|
Source(s) of funding: |
Self-finance |
||||||||||||||||||||||
|
研究疾病: |
新发糖尿病 |
||||||||||||||||||||||
|
Target disease: |
Newly diagnosed diabetes |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
连续入组 |
||||||||||||||||||||||
|
Study design: |
Sequential |
||||||||||||||||||||||
|
研究目的: |
1、探究T1DM遗传风险评分对糖尿病患者是否进展为胰岛素缺乏的预测效能; 2、比较胰岛素缺乏队列与非胰岛素缺乏队列的遗传特征的差异。 |
||||||||||||||||||||||
|
Objectives of Study: |
1. To investigate the efficacy of the T1DM genetic risk score in predicting progression to insulin deficiency in patients with diabetes mellitus; 2. To compare the differences in genetic characteristics between the insulin-deficient cohort and the non-insulin-deficient cohort. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1、已明确诊断为T1DM的患者; 2、妊娠期糖尿病、单基因糖尿病(新生儿糖尿病MODY)、胰腺外分泌疾病 (囊性纤维化病)、药物或化学物品引起的糖尿病; 3、长期使用激素或免疫抑制剂治疗者; 4、妊娠或哺乳期妇女; 5、合并其他自身免疫性疾病、恶性肿瘤、严重的肝肾疾病、尿毒症; 6、预计生存寿命不超过 3 年; 7、精神疾患或其它原因致无法配合调查者; 8、糖尿病酮症酸中毒急性期; 9、严重感染、发热、创伤、重大手术等应激情况; 10、IAA 检测需排除外源性胰岛素治疗 1 周以上; 11、主要临床信息缺乏的患者; 12、研究者认为不适合参加本研究者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1.Patients who have been clearly diagnosed with T1DM; 2.Gestational diabetes mellitus, monogenic diabetes mellitus (neonatal diabetes mellitus MODY), pancreatic exocrine disease (cystic fibrosis disease), drug or chemical-induced diabetes mellitus; 3.Long-term use of hormones or immunosuppressive drugs treatment; 4.Pregnant or breastfeeding women; 5.The combination of other autoimmune diseases, malignant neoplasms, severe liver and kidney disease, Uremia; 6. Life expectancy of not more than 3 years; 7. Mental illness or other reasons that make it impossible to cooperate with the investigation; 8. Acute stage of diabetic ketoacidosis; 9. Serious infections, fever, trauma, major surgeries, and other stressful situations; 10. Exogenous insulin treatment should be excluded from the IAA test for more than one week; 11. Patients with lack of key clinical information; 12. Patients who are not considered by the researchers to be suitable for participation in the study. The researcher believes that it is not suitable to participate in the study. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-10-01 00:00:00至 To 2029-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2025-11-07 00:00:00 至 To 2029-04-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
无 |
|
Blinding: |
None |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例数据记录表CRF |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Case Record Form |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |